Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT-Reference-Cited by-同舟云学术

Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

Published:2008 Issue:1 Volume:5 Page:5
ISSN:1742-6405
Container-title:AIDS Research and Therapy
language:en
Short-container-title:AIDS Res Ther

Author:

Smith Kimberly Y,Weinberg Winkler G,DeJesus Edwin,Fischl Margaret A,Liao Qiming,Ross Lisa L,Pakes Gary E,Pappa Keith A,Pakes C TRACEY

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Virology,Molecular Medicine

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of potential antivirals against SARS-CoV-2 using virtual screening method;Informatics in Medicine Unlocked;2021

2. STABLE LIQUID CHROMATOGRAPHY METHOD FOR THE RESOLUTION AND QUANTIFICATION OF RELATED IMPURITIES OF FOSAMPRENAVIR IN BULK AND PHARMACEUTICAL FORMULATIONS;INDIAN DRUGS;2019-09-28

3. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis;BMC Infectious Diseases;2019-05-30

4. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States;AIDS Research and Human Retroviruses;2018-08

5. Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis;HIV Medicine;2018-07-13